Journal Information
Statistics
Follow this link to access the full text of the article
Evaluation of the Impact of Elexacaftor/Tezacaftor/Ivacaftor on aerobic capacity in children with Cystic Fibrosis aged 6 to 11 years: Actual observations and clinical perspectives
Margarita Pérez-Ruiz1,2,#, Mats te Bos3,4,#, Patricia Fernández García5, Cristina de Manuel Gómez6, Ana Morales-Tirado7, Alejandro López-Neyra8, Marta Ruiz de Valbuena Maíz9, Margarita Rubio10, Verónica Sanz-Santiago11,
Corresponding author
1 ImFINE Research Group. Health and Human Performance Department. Faculty of Physical Activity and Sport Sciences. Universidad Politécnica de Madrid, Madrid, Spain
2 Departamento de Salud y Rendimiento Humano, Facultad de Ciencias de la Actividad Física y del Deporte-INEF, Universidad Politécnica de Madrid, Madrid, Spain
3 ImFINE Research Group. Health and Human Performance Department. Faculty of Physical Activity and Sport Sciences. Universidad Politécnica de Madrid, Madrid, Spain
4 Departamento de Salud y Rendimiento Humano, Facultad de Ciencias de la Actividad Física y del Deporte-INEF, Universidad Politécnica de Madrid, Madrid, Spain
5 Pediatric Pulmonology Department and Cystic Fibrosis Unit. Hospital Infantil Universitario Infantil Niño Jesús, Madrid, Spain
6 Pediatric Pulmonology Department and Cystic Fibrosis Unit, Hospital Universitario La Paz, Madrid, Spain
7 Pediatric Pulmonology Department and Cystic Fibrosis Unit. Hospital Infantil Universitario Ramón y Cajal, Madrid, Spain
8 Pediatric Pulmonology Department and Cystic Fibrosis Unit. Hospital Infantil Universitario Infantil Niño Jesús, Madrid, Spain
9 Pediatric Pulmonology Department and Cystic Fibrosis Unit, Hospital Universitario La Paz, Madrid, Spain
10 Department of Medicine. Faculty of Biomedical and Health Sciences. Universidad Europea de Madrid, Spain
11 Pediatric Pulmonology Department and Cystic Fibrosis Unit. Hospital Infantil Universitario Infantil Niño Jesús, Madrid, Spain
Ver más